Previous 10 | Next 10 |
SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, announced today that GIMOTI ® (metoclopramide) nasal spray a novel treatment solution f...
Shares of Evoke Pharma Inc. (NASDAQ:EVOK) traded at a new 52-week high today of $11.10. So far today approximately 79.3 million shares have been exchanged, as compared to an average 30-day volume of 83,000 shares. Evoke Pharma Inc is a specialty pharmaceutical company focused on the deve...
SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that together with the research team at H.C. Wainwright & Co., it will host ...
Evoke Pharma, Inc. (EVOK) Q4 2021 Earnings Conference Call March 8, 2022, 4:30 PM ET Company Participants Dave Gonyer – Chief Executive Officer Matt D’Onfrio – Chief Business Officer Chris Quesenberry – Gimoti’s Chief Commercial Officer from EVERSANA Confere...
Evoke Pharma press release (NASDAQ:EVOK): Q4 GAAP EPS of $0.05 beats by $0.13. Revenue of $0.36M (+1700.0% Y/Y) misses by $0.15M. For further details see: Evoke Pharma GAAP EPS of $0.05 beats by $0.13, revenue of $0.36M misses by $0.15M
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pha...
SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2021 financ...
SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray (GIMOTI), today ann...
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif., Feb. 17, 2022 (GLOBE NEW...
Evoke Pharma (EVOK +2.2%) and Eversana Life Science Services extended their agreement to continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the U.S. through the end of 2026. According to the original 2020 agreement, Evoke retai...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK)...